SCHEMBL22004367

SCHEMBL22004367

CC(C)n1c(-c2ccccc2)cc2cc(F)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
ACLY P53396 4/20 0.40
KMT2A Q03164 2/20 0.40
NTRK1 P04629 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
PGR P06401 1/20 0.38
CYP19A1 P11511 1/20 0.38
GRIK1 P39086 1/20 0.38
GRIK2 Q13002 1/20 0.38
ATP1A1 P05023 1/20 0.37
ATP1B1 P05026 1/20 0.37
ATP1A3 P13637 1/20 0.37
ATP1B2 P14415 1/20 0.37
ATP1A2 P50993 1/20 0.37
ATP1B3 P54709 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21244768 0.83 NR1I2 (0.48) ACLYKMT2AKDM4EALDH1A1HSD17B10
SCHEMBL11703292 0.82 KMT2A (0.59) KMT2AKDM4EALDH1A1HPGDHSD17B10
SCHEMBL22003798 0.81 ACLY (0.44) ACLYKMT2A
SCHEMBL2418905 0.81 ALDH1A1 (0.40) KMT2AKDM4EALDH1A1HSD17B10CYP19A1
SCHEMBL22003809 0.79 GRIK1 (0.62) CYP11B1CYP11B2ACLYKMT2AKDM4E
SCHEMBL11688437 0.79 KMT2A (0.66) ACLYKMT2ANTRK1KDM4EALDH1A1
SCHEMBL22003807 0.79 ACLY (0.47) CYP11B1CYP11B2ACLYKMT2AALDH1A1
SCHEMBL22004127 0.78 ACLY (0.51) ACLYKDM4EALDH1A1HPGDHSD17B10
SCHEMBL22004126 0.78 ACLY (0.45) CYP11B1CYP11B2ACLYKMT2AKDM4E
SCHEMBL10247332 0.77 KDM4E (0.42) CYP11B1CYP11B2KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF NIMBUS DISCOVERY, INC. 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF ACLY, ATP5ME, ATP5MG CYP11B1 2462/4885CYP11B2 2971/4885ACLY 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.